Cargando…

The Different Immunoregulatory Functions of Mesenchymal Stem Cells in Patients with Low-Risk or High-Risk Myelodysplastic Syndromes

Myelodysplastic syndrome (MDS) are a group of progressive, clonal, neoplastic bone marrow disorders characterized by hematopoietic stem cell dysregulation and abnormalities in the immune system. Mesenchymal stem cells (MSC) have gained further interests after the demonstration of an immunoregulatory...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Zhigang, Wang, Zhenling, Li, Qiubai, Li, Weiming, You, Yong, Zou, Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448671/ https://www.ncbi.nlm.nih.gov/pubmed/23029178 http://dx.doi.org/10.1371/journal.pone.0045675

Ejemplares similares

The Different Immunoregulatory Functions on Dendritic Cells between Mesenchymal Stem Cells Derived from Bone Marrow of Patients with Low-Risk or High-Risk Myelodysplastic Syndromes
por: Wang, Zhenling, et al.
Publicado: (2013)

Past, present and future in low-risk myelodysplastic syndrome
por: Toprak, Selami Kocak
Publicado: (2022)

Increased Apoptotic Activity in Low-Risk Myelodysplastic Syndrome
por: Park, Songyi, et al.
Publicado: (2022)

The Mesenchymal Niche in Myelodysplastic Syndromes
por: Friedrich, Chloé, et al.
Publicado: (2022)

A20 plays a critical role in the immunoregulatory function of mesenchymal stem cells
por: Dang, Rui‐Jie, et al.
Publicado: (2016)

Activation of NF-κB driven inflammatory programs in mesenchymal elements attenuates hematopoiesis in low-risk myelodysplastic syndromes
por: Ping, Zhen, et al.
Publicado: (2018)

Impaired Expression of Focal Adhesion Kinase in Mesenchymal Stromal Cells from Low-Risk Myelodysplastic Syndrome Patients
por: Wu, Yuenv, et al.
Publicado: (2017)

Differences and similarities between mesenchymal stem cell and endothelial progenitor cell immunoregulatory properties against T cells
por: Razazian, Mehdi, et al.
Publicado: (2021)

Modulation of the secretion of mesenchymal stem cell immunoregulatory factors by hydrolyzed fish collagen
por: Liu, Chao, et al.
Publicado: (2020)

miR-155 Contributes to the Immunoregulatory Function of Human Mesenchymal Stem Cells
por: Pers, Yves-Marie, et al.
Publicado: (2021)

The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification
por: Peng, Xiaohuan, et al.
Publicado: (2022)

Editorial: Risk-stratification in myelodysplastic syndromes
por: Breccia, Massimo, et al.
Publicado: (2022)

Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes
por: Hattakitpanitchakul, Saroj, et al.
Publicado: (2021)

Mesenchymal Stem Cells in Aplastic Anemia and Myelodysplastic Syndromes: The “Seed and Soil” Crosstalk
por: Fattizzo, Bruno, et al.
Publicado: (2020)

Stem Cells in the Myelodysplastic Syndromes
por: Zhan, Di, et al.
Publicado: (2021)

Hyperuricemia and acute kidney injury secondary to spontaneous tumor lysis syndrome in low risk myelodysplastic syndrome
por: Feng, Yunlin, et al.
Publicado: (2014)

Immunoregulatory Effects of Bone Marrow-Derived Mesenchymal Stem Cells in the Nasal Polyp Microenvironment
por: Pezato, Rogério, et al.
Publicado: (2014)

Immunoregulatory, proliferative and anti-oxidant effects of nanocurcuminoids on adipose-derived mesenchymal stem cells
por: Yousefi, Forouzan, et al.
Publicado: (2019)

Immunoregulatory potential of mesenchymal stem cells following activation by macrophage-derived soluble factors
por: Saldaña, Laura, et al.
Publicado: (2019)

Mechanisms behind the Immunoregulatory Dialogue between Mesenchymal Stem Cells and Th17 Cells
por: Terraza-Aguirre, Claudia, et al.
Publicado: (2020)

Immunoregulatory effect of mesenchymal stem cell via mitochondria signaling pathways in allergic asthma
por: Huang, Minmin, et al.
Publicado: (2021)

Senescent Mesenchymal Stem Cells in Myelodysplastic Syndrome: Functional Alterations, Molecular Mechanisms, and Therapeutic Strategies
por: Chen, Xiaofang, et al.
Publicado: (2021)

Utility of the p53 mutant protein in patients with low-risk myelodysplastic syndrome
por: Yao, David C., et al.
Publicado: (2014)

Successful Treatment of Hemophagocytic Lymphohistiocytosis Associated with Low-risk Myelodysplastic Syndrome by Azacitidine
por: Daitoku, Shinya, et al.
Publicado: (2018)

Cytokine expression patterns and mesenchymal stem cell karyotypes from the bone marrow microenvironment of patients with myelodysplastic syndromes
por: Xiong, H., et al.
Publicado: (2015)

Risk stratification in therapy-related myelodysplastic syndromes
por: Zeidan, Amer M.
Publicado: (2017)

Management of patients with lower-risk myelodysplastic syndromes
por: Brunner, Andrew M., et al.
Publicado: (2022)

Enhancement of Immunoregulatory Function of Modified Bone Marrow Mesenchymal Stem Cells by Targeting SOCS1
por: Zhang, Xiaoming, et al.
Publicado: (2018)

Role of PD-L1 in licensing immunoregulatory function of dental pulp mesenchymal stem cells
por: Di Tinco, Rosanna, et al.
Publicado: (2021)

Part 4: Myelodysplastic syndromes—Treatment of low-risk patients with the 5q deletion
por: Magalhães, Silvia Maria Meira, et al.
Publicado: (2018)

Immunoregulatory impact of human mesenchymal-conditioned media and mesenchymal derived exosomes on monocytes
por: Tokhanbigli, Samaneh, et al.
Publicado: (2019)

Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes
por: Mosquera Orgueira, Adrian, et al.
Publicado: (2023)

EASIX for prediction of survival in lower-risk myelodysplastic syndromes
por: Merz, Almuth, et al.
Publicado: (2019)

Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes
por: Tinsley-Vance, Sara M., et al.
Publicado: (2023)

Personalized risk model for predicting risk of acute coronary syndrome in patients with myelodysplastic syndromes
por: Montarello, Natalie, et al.
Publicado: (2023)

Effect of DiD Carbocyanine Dye Labeling on Immunoregulatory Function and Differentiation of Mice Mesenchymal Stem Cells
por: Mohtasebi, Maryam Sadat, et al.
Publicado: (2014)

Overexpression of soluble RAGE in mesenchymal stem cells enhances their immunoregulatory potential for cellular therapy in autoimmune arthritis
por: Park, Min-Jung, et al.
Publicado: (2016)

B Lymphocytes Are the Target of Mesenchymal Stem Cells Immunoregulatory Effect in a Murine Graft-versus-Host Disease Model
por: Lu, Di, et al.
Publicado: (2019)

An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome
por: Martini, M, et al.
Publicado: (2015)

Part 3: Myelodysplastic syndromes—Treatment of low-risk patients without the 5q deletion
por: Velloso, Elvira Deolinda Rodrigues Pereira, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mdubv7ildnmmupe608g3b36srt